Advances in our understanding of cancer biology through research and big data analysis are accelerating our ability to identify new methods for treating cancer and improving patient outcomes. Transforming these insights into diagnostics and therapeutics requires national and global, collaborative partnerships committed to evaluating these technologies in high quality and innovative clinical trials.
As Canada’s largest cooperative oncology group, with a global reputation for quality clinical trials in cancer therapy, supportive care and prevention our expertise touches every aspect of cancer trials.
Our scientific agenda, developed by clinical researchers across Canada, includes trials of new cancer agents, novel radiation and surgical techniques, as well as interventions to improve quality of life for cancer patients.
We have a reputation for quality trials
Our commitment to safety and quality is globally recognized, and we conduct trials that can be used for regulatory submissions, creating productive industry partnerships. With over 35 years of experience, we have the capability and expertise to host all phases of clinical trials.
We are globally connected
CCTG’s brain bank includes top clinicians and scientists from across the country, as well as global collaborations with groups in 40 countries. Along with being a national program of the Canadian Cancer Society Research Institute, CCTG is the only non-U.S. partner in the National Clinical Trials Network,
Our partnering organizationsEuropean Organization for Research and Treatment of Cancer (EORTC), The Gynecological Cancer Intergroup, The Breast Cancer Intergroup, Australasian Lung Cancer Trials Group (ALTG), Intergroup Francophone de Cancerologie, Thoracique (IFCT).
We are leaders in economic analysis and patient-recorded outcomes
The Committee on Economic Analysis (CEA) at CCTG incorporates economic factors in their studies, and is the only formal economic committee within a cooperative clinical trials group worldwide. We incorporate cost effectiveness, while conducting trials assessing the comparative effectiveness of cancer therapies.
We are looking at what is next
CCTG is building expertise to evaluate precision cancer medicine approaches. Identifying biomarkers will improve outcomes and develop groundbreaking approaches to cancer trial design.
We use trial data to transform the future
The Tumour Tissue Data Repository (TTDR) at CCTG houses twenty years of bio-specimens linked to clinical trial data. This repository is crucial to the development of targeted therapies, and includes demographic, patient characteristics, treatments given, toxicities, and multiple outcome measurements.
We want to work with you
The groups’ success is founded on a cooperative approach, partnering for mutual benefit and working towards a shared goal to fight cancer. Our work requires investment in order to leverage our expertise and infrastructure. In return, we offer solid experience, full project management and a network of leading researchers and institutional support to tackle questions and lead change.
Contact us to discuss opportunities to partner:
Dr. Janet Dancey, CCTG Scientific Director | 613-533-6430 | email@example.com